Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Drug Investigation
Published in: Clinical Drug Investigation 10/2001

01-10-2001 | Clinical Use

Ademetionine 1, 4- Butanedisulphonate vs Traditional Chinese Medicine for the Treatment of Acute Viral Hepatitis with Hepatocellular Jaundice

Author: Dr Wang Bao-en

Published in: Clinical Drug Investigation | Issue 10/2001

Login to get access

Abstract

Objective

To compare the efficacy of ademetionine 1, 4-butanedisulphonate (Ade-SD/4) versus a traditional Chinese remedy (TCR) in patients with hepatocellular jaundice associated with acute viral hepatitis.

Patients

253 patients were enrolled and 148 completed the study.

Methods

In this randomised, open-label, multicentre, parallel-group study, patients (aged 14 to 65 years) with elevated serum bilirubin levels (>2 × upper limit of normal) received either Ade-SD4 (ademetionine 1g) intravenously once daily for 2 weeks then oral Ade-SD4 (ademetionine 0.5g) twice daily for 4 weeks, or TCR (Capillarin, a herbal derivative, 30ml intravenously once daily for 2 weeks, then oral Capillarin 30ml for 4 weeks plus six tablets of Tanshinone, a Salvia miltiorrhiza derivative, once daily throughout the 6 weeks). Treatment efficacy was evaluated by changes in serum bilirubin (total and conjugated) and transaminases, fatigue and jaundice after 7, 14, 28 and 42 days.

Results

Both Ade-SD4 (n = 132) and TCR (n = 121) significantly improved serum transaminases, albumin, alkaline phosphatase, γ-glutamyl transferase and total bile acids; improvements in serum total and conjugated bilirubin and alanine amino transferase (ALT) were significantly greater with Ade-SD4 than with TCR. After 7 days of treatment, median total bilirubin was 2.23 mg/dl in Ade-SD4-treated patients vs 3.08 mg/dl in TCR-treated patients (p = 0.0001), while conjugated bilirubin and ALT were, respectively, 0.97 vs 1.5 mg/dl (p = 0.0001) and 116 vs 162 U/L (p = 0.0006). At day 7, the proportion of serum total and conjugated bilirubin responders was significantly higher in the Ade-SD4 group (69 and 73%, respectively) than in the TCR group (50 and 54%, respectively; p ≤ 0.004). Significant differences in favour of Ade-SD4 were observed for jaundice (p = 0.01), fatigue (p = 0.004), general discomfort (p = 0.05), urinary discoloration (p = 0.02), nausea (p = 0.01), anorexia (p = 0.001), and patient (p = 0.01) and physician (p = 0.05) assessments of treatment efficacy. Both treatments were well tolerated and no serious adverse effects were reported.

Conclusion

Ade-SD4 is significantly more effective than TCR in reducing the severity and duration of hepatocellular jaundice associated with acute viral hepatitis.
Literature
1.
OcknerRK. Acute viral hepatitis. In: Wyngaarden JB, Smith LH Jr, Bennett JC, editors. Cecil’s Textbook of Medicine. 19th ed. Philadelphia: Saunders, 1992: 763–71
2.
Tsai CC, Kao CT, Hsu CT, et al. Evaluation of four prescriptions of traditional Chinese medicine: syh-mo-yiin, guizhi-fuling-wan, shieh-qing-wan and syh-nih-sann on experimental acute liver damage in rats. J Ethnopharmacol 1997; 55: 213–22PubMedCrossRef
3.
Tsai CC, Kao ST, Hsu CT, et al. Ameliorative effect of traditional Chinese medicine prescriptions on alpha-naphthylisothiocyanate and carbon-tetrachloride induced toxicity in rats. Am J Chin Med 1997; 25: 185–96PubMedCrossRef
4.
Lin SC, Lin CC, Lu FJ, et al. Protective and therapeutic effects of huanglian-jie-du-tang on hepatotoxin-induced liver injuries. Am J Chin Med 1996; 24: 219–29PubMedCrossRef
5.
6.
Chawla RK, Lewis FW, Kutner MH, et al. Plasma cysteine, cystine, and glutathione in cirrhosis. Gastroenterology 1984; 87: 770–6PubMed
7.
Arias IM. Mechanisms and consequences of ion transport in the liver. In: Popper H, Schaffner F, editors. Progress in liver diseases. New York: Grune & Stratton, 1986: 145–59
8.
Boelsterli UA, Rakhit G, Balazs T. Modulation of S-adenosyl-L-methionine of hepatic Na+, K+-ATPase, membrane fluidity, bile flow in rats with ethynylestradiol-induced cholestasis. Hepatology 1983; 3: 12–7PubMedCrossRef
9.
Vendemiale G, Altomare E, Trizio T, et al. Effects of S-adenosyl-L-methionine on hepatic glutathione in patients with liver disease. Scand J Gastroenterol 1989; 24: 407–15PubMedCrossRef
10.
Martín-Duce A, Ortiz P, Cabrero C, et al. S-adenosyl-L-methionine synthetase and phospholipid methyltransferase are inhibited in human cirrhosis. Hepatology 1988; 8: 65–8CrossRef
11.
Bonfirraro G, Chieffi O, Quinti R, et al. S-adenosyl-L-methionine (SAMe)-induced amelioration of intrahepatic cholestasis of pregnancy. Results of an open study. Clin Drug Invest 1990; 2: 125–8CrossRef
12.
Frezza M, Surrenti C, Manzillo G, et al. Oral S-adenosyl-methionine in the symptomatic treatment of intra-hepatic cholestasis. A double-blind, placebo-controlled study. Gastroenterology 1990; 99: 211–5PubMed
13.
Frezza M, Centini G, Cammareri G, et al. S-adenosylmethionine for the treatment of intrahepatic cholestasis of pregnancy. Results of a controlled clinical trial. Hepatogastroenterology 1990; 37Suppl. 2: 122–5PubMed
14.
Frezza M, Pozzato G, Chiesa L, et al. Reversal of intrahepatic cholestasis of pregnancy in women after high dose S-adenosyl-L-methionine administration. Hepatology 1984; 4: 274–8PubMedCrossRef
15.
Almasio P, Bortolini M, Pagliaro L, et al. Role of S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis. Drugs 1990; 40Suppl. 3: 111–23PubMedCrossRef
16.
Qin B, Guo S, Zhao Y, et al. A trial of ademetionine in the treatment of intrahepatic biliary stasis viral hepatitis. Zhonghua Gan Zang Bing Za Zhi 2000; 8: 158–60PubMed
17.
Catalino F, Scarponi S, Cesa F, et al. Efficacy and safety of intravenous S-adenosyl-L-methionine therapy in the management of intrahepatic cholestasis of pregnancy. Clin Drug Invest 1992; 4: 78–82CrossRef
18.
Manzillo G, Piccinino F, Surrenti C, et al. Multicentre double-blind placebo-controlled study of intravenous and oral S-adenosyl-1-methionine (SAMe) in cholestatic patients with liver disease. Clin Drug Invest 1992; 4Suppl. 4: 90–100
19.
Botero RC, Delgado C. Placebo controlled trial of intravenous adenosylmethionine (SAMe) in patients with acute hepatitis A, B and NANB [abstract]. Hepatology 1991; 14: 199A
20.
Liu J, Shen HM, Ong CN. Salvia miltiorrhiza inhibits cell growth and induces apoptosis in human hepatoma HepG(2) cells. Cancer Lett 2000; 153: 85–93PubMedCrossRef
21.
Li CX, Li L, Lou J, et al. The protective effects of traditional Chinese medicine prescription han-dan-gan-le, on CC14-induced liver fibrosis in rats. Am J Chin Med 1998; 26: 325–32PubMedCrossRef
22.
Ryu SY, Lee CO, Choi SU. In vitro cytotoxicity of tanshinones from Salvia miltiorrhiza. Planta Med 1997; 63: 339–42PubMedCrossRef
23.
Wang X, Yuan S, Wang C. Apreliminary study of the anti-cancer effect of tanshinone on hepatic carcinoma and its mechanism of action in mice. Zhonghua Zhong Liu Za Zhi 1996; 18: 412–14PubMed
24.
Yin J, Wennberg RP, Miller M. Induction of hepatic bilirubin and drug metabolizing enzymes by individual herbs present in the traditional Chinese medicine, yin zhi huang. Dev Pharmacol Ther 1993; 20: 186–94PubMed
25.
Zhang BZ, Ding F, Tan LW. Clinical and experimental study on yi-gan-ning granule in treating chronic hepatitis B. Zhongguo Zhong Xi Yi Jie He Za Zhi 1993; 13: 597–9PubMed
26.
Chen Z. Clinical study of 96 cases with chronic hepatitis B treated with jiedu yanggan gao by a double-blind method. Zhong Xi Yi Jie He Za Zhi 1990; 10: 71–4PubMed
27.
Ng TB, Liu F, Wang ZT. Antioxidative activity of natural products from plants. Life Sci 2000; 66: 709–23PubMedCrossRef
28.
Niu XL, Ichimori K, Yang X, et al. Tanshinone II-Ainhibits low density lipoprotein oxidation in vitro. Free Radic Res 2000; 33: 305–12PubMedCrossRef
29.
Chu CY, Tseng TH, Hwang JM, et al. Protective effects of capillarisin on tert-butylhydroperoxide-induced oxidative damage in rat primary hepatocytes. Arch Toxicol 1999; 73: 263–8PubMedCrossRef
30.
Zhou GY, Zhao BL, Hou JW, et al. Protective effects of sodium tanshinone IIA sulphonate against adriamycin-induced lipid peroxidation in mice hearts in vivo and in vitro. Pharmacol Res 1999; 40: 487–91PubMedCrossRef
31.
Cao EH, Liu XQ, Wang JJ, et al. Effect of natural antioxidant tanshinone II-A on DNA damage by lipid peroxidation in liver cells. Free Radie Biol Med 1996; 20: 801–6CrossRef
32.
Zhao BL, Jiang W, Zhao Y, et al. Scavenging effects of Salvia miltiorrhiza on free radicals and its protection for myocardial mitochondrial membranes from ischemia-reperfusion injury. Biochem Mol Biol Int 1996; 38: 1171–82PubMed
33.
34.
Adachi Y, Nanno T, Kanbe A, et al. The effects of S-adenosyl-L-methionine on intrahepatic cholestasis. Jap Arch Int Med 1986; 33: 185–92
35.
Marchesini G, Bugianesi E, Bianchi G, et al. Effect of S-adenosyl-L-methionine administration on plasma levels of sulfur-containing amino acids in patients with liver cirrhosis. Clin Nutr 1992; 11: 303–8PubMedCrossRef
36.
Heaton KW Bile salts. In: Wright R, editor. Liver and biliary disease. Eastbourne (UK): Bailliere Tindall, 1985
Metadata
Title
Ademetionine 1, 4- Butanedisulphonate vs Traditional Chinese Medicine for the Treatment of Acute Viral Hepatitis with Hepatocellular Jaundice
Author
Dr Wang Bao-en
Publication date
01-10-2001
Publisher
Springer International Publishing
Published in
Clinical Drug Investigation / Issue 10/2001
Print ISSN: 1173-2563
Electronic ISSN: 1179-1918
DOI
https://doi.org/10.2165/00044011-200121100-00003

Other articles of this Issue 10/2001

Clinical Drug Investigation 10/2001 Go to the issue

Clinical Use

Treatment of Dyslipidaemia with Fluvastatin in Patients with Type 2 Diabetes Mellitus

Clinical Epidemiology

Factors Affecting the Unplanned Hospital Readmission of Elderly Patients with Cardiovascular Disease

Clinical Use

Antipsychotic Drug Prescription in a Serbian Long-Stay Psychiatric Care Facility

Short Communication

Modifying Clinical Trial Designs to Test Treatments for Clinical Significance in Individual Patients

Clinical Pharmacokinetics

Menstrual Cycle and Zidovudine Pharmacokinetics in HIV-Infected Women

Clinical Use

A Comparison of Fluticasone Propionate, 100μg Twice Daily, Administered Via a CFC and Non-CFC Propellant, HFA 134a, in Adult Patients with Asthma